Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.
Consumers are focusing on experiences rather than material goods, and restaurants are in the sweet spot to take advantage of this “experiential economy.” ...